JP Morgan Maintains Overweight on Qiagen, Lowers Price Target to $45

Benzinga Newsdesk www.benzinga.com Negative 83.1%

Neg 83.1% Neu 0% Pos 0%

JP Morgan analyst Casey Woodring maintains Qiagen (NYSE:QGEN) with a Overweight and lowers the price target from $60 to $45.